

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.



CARDIOLOGY  
JOURNAL

ISSN: 1897-5593

e-ISSN: 1898-018X

## Differences in coronary microcirculation measurements during regadenoson vs. adenosine - induced hyperemia

**Authors:** Rafał Januszek, Wojciech Siłka, Natalia Bukała, Michał Chyrchel, Wojciech Wańha, Andrzej Surdacki, Stanisław Bartuś

**DOI:** 10.5603/cj.97857

**Article type:** Original Article

**Submitted:** 2023-10-16

**Accepted:** 2024-10-18

**Published online:** 2024-12-20

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited.

Articles in "Cardiology Journal" are listed in PubMed.

## ORIGINAL ARTICLE

### **Differences in coronary microcirculation measurements during regadenoson vs. adenosine – induced hyperemia**

Running title: **Regadenoson vs. adenosine in coronary microcirculation assessment**

Rafał Januszek<sup>1, 2</sup>, Wojciech Siłka<sup>3</sup>, Natalia Bukala<sup>3</sup>, Michał Chyrchel<sup>1, 4</sup>, Wojciech Wańha<sup>5</sup>, Andrzej Surdacki<sup>1, 4</sup>, Stanisław Bartuś<sup>1, 4</sup>

<sup>1</sup>Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, Poland

<sup>2</sup>Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland

<sup>3</sup>Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

<sup>4</sup>Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

<sup>5</sup>Department of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland

**Corresponding author:** Rafał Januszek, M.D., Ph.D., Department of Cardiology and Cardiovascular Interventions, University Hospital in Krakow, Kopernika 17, 31-501 Krakow, Poland, tel: +48 12 424 71 70, fax: +48 12 424 71 80, e-mail: [jaanraf@interia.pl](mailto:jaanraf@interia.pl)

**Date submitted:** 16.10.2023

**Date accepted:** 18.10.2024

**Early publication date:** 20.12.2024

DOI: [10.5603/cj.97857](https://doi.org/10.5603/cj.97857)

## ABSTRACT

**Background:** Little is known about the similarity of microcirculation assessment outcomes performed with regadenoson and adenosine. The aim of the current study was to compare coronary flow reserve (CFR) and index of microcirculatory resistance (IMR) assessment using adenosine and regadenoson, and to evaluate predictors regarding the size of differences.

**Methods:** 44 patients were enrolled and diagnosed between 2021 and 2023. Fractional flow reserve (FFR), CFR and IMR were measured twice in the circumflex (Cx) (n = 8) or left anterior descending (LAD) (n = 36) artery: once with continuous infusion of adenosine (Adenocor 140 µg/kg/min) and 10 minutes later with regadenoson (Rapiscan 400 µg *i.v.*).

**Results:** Averaged results were quantified with adenosine and regadenoson for FFR (0.81 [0.75 ÷ 0.89] vs. 0.80 [0.73 ÷ 0.88]), CFR (3.84 [1.67 ÷ 4.08] vs. 3.97 [1.78 ÷ 4.32]) and IMR (20.01 [11 ÷ 24.5] vs. 20.25 [10.75 ÷ 23]), respectively. None of the differences were statistically significant. Among the significant ( $p < 0.05$ ) predictors of greater  $\Delta$ CFR, the following can be noted: prior percutaneous transluminal angioplasty/carotid artery stenting ( $\beta = 2.35$ ), oral anticoagulant usage ( $\beta = 0.89$ ), and prior stroke/transient ischaemic attack (TIA) ( $\beta = 1.09$ ), with the latter being also confirmed for greater  $\Delta$ IMR ( $\beta = 8.89$ ). Moreover, patients with New York Heart Association (NYHA) class II/III, as compared to those with NYHA class I, were more likely to have greater  $\Delta$ IMR ( $\beta = 11.89$ ).

**Conclusions:** Regadenoson may be a feasible alternative to adenosine in coronary microcirculation assessment, as it produces similar outcomes. Selected factors were found to be predictors of greater differences in IMR, CFR and FFR values according to the agent used for coronary hyperemia.

**Keywords:** adenosine, coronary flow reserve, fractional flow reserve, index of microcirculation resistance, regadenoson

## Introduction

Assessment of coronary microvascular circulation, *i.e.* coronary flow reserve (CFR) and index of microcirculatory resistance (IMR), are among the most effective indicators for assessing myocardial blood supply and functional abnormalities of the coronary arteries in patients without obstructive coronary artery disease and symptomatic angina or heart failure. In multiple, heretofore published studies, the usefulness has been presented of microcirculation testing, as its outcomes are associated with patients' prognosis as well as concomitant diseases and major adverse cardiac event (MACE) occurrence in selected patient subgroups [1–7]. Moreover, such assessment could potentially provide further insight into patients' underlying disease, which regular coronary angiography often omits [8].

It is crucial for measurements to be performed correctly, *i.e.* under conditions of maximum passive hyperemia. To do so, adenosine infusion is considered as the gold standard. However, it may initiate side effects, such as shortness of breath, bronchospasm, flushing, chest pain and transient atrioventricular conduction block [9]. Hence, in certain subgroups of patients, such as in those with a contraindication to using adenosine, *i.e.* with reactive airway diseases, it is convenient to introduce regadenoson instead. It works as a more selective agent and can be administered as a simple bolus via peripheral line. Therefore, it provokes a smaller number of side effects [9]. Importantly, regadenoson was proved to be equivalent to adenosine for FFR assessment [10, 11]. However, there are concerns regarding its feasibility in the CFR and IMR assessments. Studies reported that regadenoson-induced hyperemia is stable, similar to adenosine time-wise, and produces fewer side effects in patients with stable coronary artery disease (CAD) [9, 12]. However, there is a lack of solid data on measurement similarity with adenosine, and overall, the data regarding regadenoson usage during an invasive microcirculatory assessment remains insufficient.

The current study was aimed at identifying whether adenosine and regadenoson used for hyperaemia deliver similar results, and as well other factors, which can influence the difference in FFR, CFR and IMR measurements — using adenosine or regadenoson.

## **Methods**

### ***Population***

Coronary microcirculation measurements were analyzed in 44 patients admitted to the invasive cardiology department from 2021 to 2023 with a suspicion of CAD. Patients with indications for physiologically-guided assessment of coronary lesions (with a stenosis of 40 to 80% on visual examination) were eligible for the study. All participants provided their written informed consent. The bioethics committee of the documented university approved the study design (No. 1072.6120.27.2022). The study was conducted in line with the 1964 Declaration of Helsinki.

### ***Physiological examination of coronary arteries with use of adenosine and regadenoson***

The examination of the coronary microcirculation was performed during a single angiographic procedure. The FFR, IMR and CRF were measured twice on the same artery. Angiography was performed in the 8 circumflex coronary arteries (Cx) and in the 36 left anterior descending coronary arteries (LAD).

To achieve maximal hyperemia, continuous infusion of adenosine *via* a peripheral vein was administrated at the dosage of 140 µg/kg/min. Measurements were taken using the dedicated Abbott PressureWire™ X pressure guidewire (Abbott Vascular, Santa Clara, CA). FFR was calculated as the lowest average distal pressure (Pd)/aortic pressure (Pa) from 3 consecutive heartbeats during maximal hyperemia. CFR was calculated as the ratio of mean transit time (Tmn) at rest/hyperemic Tmn, whereas IMR was calculated from the Pd × Tmn equation

determined during hyperemia. After the cessation of adenosine, *i.e.*, 10 minutes, a regadenoson test was performed. To achieve maximal hyperemia in this case, 400 µg of regadenoson (Rapiscan 1 amp. 400 mcg, GE Healthcare AS, Nycoveien 1, Norway) was administered through the peripheral line as a 4-ml bolus (10-second-long infusion) followed by a 10-ml NaCl flush.

### ***Statistical analysis***

The analysis of quantitative variables was carried out by calculating the mean, standard deviation, median and quartiles. Analysis of qualitative variables was performed by calculating the number and percentage of occurrences for each value. Univariate analyses of the effect of each potential variable predictor on  $\Delta$ FFR,  $\Delta$ CFR and  $\Delta$ IMR (quantitative variables) were performed using linear regression. The results were presented as regression model parameter values. The normality of variable distribution was checked using the Shapiro-Wilk test. Comparisons regarding the values of quantitative variables in two repeated measures was performed using the Wilcoxon paired *t*-test. A non-parametric test was used because the differences in the studied parameters were not normally distributed. The analysis assumed a significance level of 0.05. Thus, all *p*-values below 0.05 were interpreted as indicating significant relationships. Analysis was performed using the R Core Team (2022). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria (<https://www.R-project.org/>).

## **Results**

### ***General characteristics***

The study included 44 patients (37 males) undergoing coronary angiography, and their general characteristics are shown in Tables 1 and 2. The mean age of the population was

66.82 ( $\pm$  8.02) years. The majority of patients clinically presented with Canadian Cardiovascular Society (CCS) 1 (54.5%), whereas half of study group had New York Heart Classification (NYHA) class II or above (50%). In terms of cardiovascular risk factors, most patients displayed arterial hypertension (86.4%) and hyperlipidemia (79.6%). Furthermore, prior percutaneous coronary intervention (PCI) (63.6%) and myocardial infarction (MI) in (56.8%) were frequent in the studied population. There were also 16 (36.4%) patients with a history of nicotine dependence in their medical records. Almost one-third of the patients (29.6%) presented symptoms of heart failure and diabetes mellitus. Furthermore, more than half of the patients had evinced hypokinesia during routine echocardiography, while mean left ventricle ejection fraction (LVEF) totalled  $46.8 \pm 15.2\%$  (Table 5).

### ***Biochemical indices***

As is shown in Table 3, there were no abnormalities found in the investigated biochemical indices among the study group.

### ***Pharmacotherapy***

By analyzing medical records, almost all patients received acetyl-salicylic acid (ASA) (88.6%) and statins (84.1%) at baseline. As the vast majority of the patients were struggling with arterial hypertension, most of them had taken at least 2 blood-pressure-lowering drugs such as beta-blockers (75.0%), angiotensin-converting enzyme inhibitors (ACEIs) (61.4%), diuretics (31.8%) and calcium channel blockers (CCBs) (25.0%). What is worth mentioning, almost half of the study group had taken proton-pump inhibitors (PPIs) (47.7%). Selected patients received P2Y<sub>12</sub> inhibitors (18.2%), oral anticoagulants (OACs; 15.9%) and clopidogrel (15.9%). More details are shown in Table 4.

### ***Comparison between regadenoson and adenosine in FFR, CFR and IMR values***

Measurements were conducted in the LAD (n = 36) and Cx arteries (n = 8). The median FFR was high in both cases, when using adenosine and regadenoson (0.81 [0.75 ÷ 0.89] and 0.80 [0.73 ÷ 0.88], respectively). No significant differences were noted between FFR, CFR and IMR values in the compared study groups (Fig. 1). The difference between measurements with adenosine and regadenoson proceeded on the same artery were:  $\Delta\text{FFR} = 0.02$  (0.01 ÷ 0.04),  $\Delta\text{CFR} = 0.6$  (0.29 ÷ 1.55) and  $\Delta\text{IMR} = 3.5$  (1.38 ÷ 7.1) (Tab. 6).

### ***Factors related to change between coronary circulation measurements when using adenosine vs. regadenoson — linear regression models***

It was revealed that CAD presence and ASA usage were significant predictors of smaller absolute  $\Delta\text{FFR}$  between compared microcirculation methods ( $\beta = -0.06$ ,  $p = 0.006$  and  $\beta = -0.03$ ,  $p = 0.046$ , respectively; Fig. 2). On the other hand, prior percutaneous transluminal angioplasty/carotid artery stenting (PTA/CAS) was proved to be a significant predictor of increased  $\Delta\text{FFR}$  ( $\beta = 0.046$ ,  $p = 0.01$ ; Fig. 2).

When considering  $\Delta\text{CFR}$ , the following predictors of its change could be observed: CAD ( $\beta = -2.15$ ,  $p < 0.001$ ), prior PTA/CAS ( $\beta = 2.35$ ,  $p < 0.001$ ), history of stroke/transient ischemic attack (TIA) ( $\beta = 1.09$ ,  $p = 0.03$ ), ASA and OACs usage ( $\beta = -1.31$ ,  $p = 0.009$  and  $\beta = 0.89$ ,  $p = 0.04$ , respectively). Furthermore, on average, for every increase in left ventricle ejection fraction by 1%, the  $\Delta\text{CFR}$  decreased by 0.02 ( $\beta = -0.02$ ,  $p = 0.049$ , Fig. 2).

Similar to previous results, the use of ASA was related to reduced  $\Delta\text{IMR}$  ( $\beta = -8.66$ ,  $p = 0.03$ ), whereas a history of stroke/TIA predicted an increment in  $\Delta\text{IMR}$  ( $\beta = 8.9$ ,  $p = 0.03$ ). Moreover, as compared to NYHA I class, the presence of II/III class was also related to increased absolute  $\Delta\text{IMR}$  ( $\beta = 11.89$ ,  $p = 0.02$ ; Fig. 2).



## Discussion

Contrary to the assessment of FFR, there is limited data regarding regadenoson usage in microcirculation coronary circulation assessments. The present analysis is one of the first to provide insight into this issue. The main findings of the current study are as follows:

- 1) there were no significant differences in the average FFR, CFR or IMR values in assessments with regadenoson as compared to adenosine;
- 2) heightened differences in the microcirculatory measures were predicted by the following: history of stroke/TIAs, prior PTA/CAS, OACs usage, more advanced NYHA class;
- 3) treatment with ASA and a diagnosis of CAD at baseline as well as LVEF values were predictors of decreased differences in microcirculatory assessments obtained with regadenoson and adenosine.

In general, regadenoson is a selective agonist of  $A_{2a}$  receptors, which along with its reversibility, is associated with a lower risk of adverse effects among patients. This also included those with comorbidities, and overall, contraindications to regular adenosine usage [13]. Moreover, in other studies, it has been reported that maximal hyperemia can be achieved faster with regadenoson, underscoring further the favorable outcomes of its usage [14]. This, sequentially, in light of the facts that its infusion preparation and administration are simpler than Adenosine infusion, reduces time spent in catheterization laboratory as well [9, 15]. Despite the aforementioned advantages, regadenoson poses several limitations. Firstly, its implementation may produce higher costs [16]. Moreover, the necessity for reliable microcirculatory assessment stability of hyperaemia induced by this agent is still a subject of debate. This is due to the fact that regadenoson was reported to have a varying duration of hyperemic effect, which considering guidelines recommending its single-dose administration, produce uncertainty whether the operator was provided enough time to

perform a reliable assessment [17]. Therefore, in patients characterised with complex lesions necessitating multiple coronary flow measurements and additional pullback recordings, adenosine remained superior.

Regarding FFR, the present study confirms a lack of significant differences between the adenosine and regadenoson approach. The reliability of the latter in FFR measurements has been reported in a number of other studies [9–12, 17–20]. For instance, in a study conducted by Nair *et al.*, the authors revealed excellent correlations between regadenoson and adenosine in lesion assessment ( $R = 0.99$ ,  $p < 0.001$ ) [10].

Given the results of the current study, it can be concluded that regadenoson is a valid tool in invasive coronary flow and IMR testing among patients with high FFR (averaged on the whole population). However, as several predictors of larger disparities between two hyperemia-inducing agents were indentified, the reproducibility of our results in other clinical situations are called to question. Since we did not explore the characteristics of these changes regarding the value in measurements between adenosine vs. regadenoson testing, the discussion at this point should be extrapolated carefully. It was observed, for example, that a history of stroke/TIA, prior PTA/CAS and higher NYHA class were significant predictors of increased discrepancies between investigated hyperemia-inducing agents. It may be the case that the epicardial and microcirculatory flows among patients characterized by a more serious “clinical burden” were more prone to changes, given the fact that the procedure was prolonged. Overall, to decisively confirm regadenoson feasibility, more focus needs to be placed on specific patient cohorts as well as and specific lesion characteristics, which the present study lacked.

Despite the fact that the means of measurements for IMR and CFR do not significantly differ statistically, insight into the pairs shows that some of the measurements differed dramatically depending on the use of regadenoson or adenosine for the induction of passive hyperemia.

There are certainly a number of factors beyond those found to be significant in the statistical analysis, and from present observations, these certainly include hemodynamic conditions that change throughout the study. It should be noted that the regadenoson and adenosine assays were performed at least 10 minutes apart. During this time, some patients' blood pressure changed, some calmed down during the examination, while some began to get nervous, *e.g.* due to back pain or to other parts of the skeletal system. Another factor that affects the hemodynamic of circulation is the temperature in the laboratory, which in many patients, causes a feeling of cold and the consequences associated with it. Another problem is keeping the guidewire in the same place in both chambers. While waiting for the next measurement, the guidewire often migrates with consecutive heartbeats, and it becomes necessary to correct the guidewire position before subsequent measurements.

To sum up, it is often not possible to create the same hemodynamic conditions for both measurements, which could certainly have influenced the obtained results. This occurs despite the determinations being made by experienced operators.

### ***Limitations***

There are some limitations of the present study, including the relatively small group of studied patients, although sufficient statistical power was achieved to draw the discussed conclusions. Furthermore, focus was not put onto differentiating whether the change in differences between adenosine and regadenoson testing was due to the former or latter agent while considering a predicting factor. Nevertheless, the envisaged hope is that there will be a further continuation of the study and enlargement of the study group.

### **Conclusions**

From the preliminary findings, it can be suggested that regadenoson is a feasible alternative

to adenosine in microcirculation assessment, as it produces similar outcomes. Selected factors were found to be predictors of greater differences in IMR, CFR and FFR values according to the agent used for coronary hyperemia.

**Data availability statement:** Data are available on special request.

**Ethics statement:** The study was approved by the local bioethics committee and was conducted in line with the 1964 Declaration of Helsinki.

**Author contributions:** R.J. — conducting the study, gathering data, preparing manuscript, organising statistician, supervising, S.B., R.J — projecting the study, W.S., N.B. — preparing and gathering data, writing draft of the manuscript, A.S., W.W. — editing manuscript, supervising.

**Funding:** None.

**Acknowledgments:** None.

**Conflict of interest:** None.

## References

1. Díez-Delhoyo F, Gutiérrez-Ibañes E, Loughlin G, et al. Coronary physiology assessment in the catheterization laboratory. *World J Cardiol.* 2015; 7(9): 525–538, doi: [10.4330/wjc.v7.i9.525](https://doi.org/10.4330/wjc.v7.i9.525), indexed in Pubmed: [26413229](https://pubmed.ncbi.nlm.nih.gov/26413229/).
2. Radhakrishnan A, Pickup LC, Price AM, et al. Coronary microvascular dysfunction is associated with degree of anaemia in end-stage renal disease. *BMC Cardiovasc Disord.* 2021; 21(1): 211, doi: [10.1186/s12872-021-02025-2](https://doi.org/10.1186/s12872-021-02025-2), indexed in Pubmed: [33902440](https://pubmed.ncbi.nlm.nih.gov/33902440/).
3. De Bruyne B, Hersbach F, Pijls NH, et al. Abnormal epicardial coronary resistance in patients with diffuse atherosclerosis but "Normal" coronary angiography. *Circulation.* 2001; 104(20): 2401–2406, doi: [10.1161/hc4501.099316](https://doi.org/10.1161/hc4501.099316), indexed in Pubmed: [11705815](https://pubmed.ncbi.nlm.nih.gov/11705815/).
4. McGeoch R, Watkins S, Berry C, et al. The index of microcirculatory resistance measured acutely predicts the extent and severity of myocardial infarction in patients

- with ST-segment elevation myocardial infarction. *JACC Cardiovasc Interv.* 2010; 3(7): 715–722, doi: [10.1016/j.jcin.2010.04.009](https://doi.org/10.1016/j.jcin.2010.04.009), indexed in Pubmed: [20650433](https://pubmed.ncbi.nlm.nih.gov/20650433/).
5. Ford TJ, Stanley B, Sidik N, et al. 1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA). *JACC Cardiovasc Interv.* 2020; 13(1): 33–45, doi: [10.1016/j.jcin.2019.11.001](https://doi.org/10.1016/j.jcin.2019.11.001), indexed in Pubmed: [31709984](https://pubmed.ncbi.nlm.nih.gov/31709984/).
  6. Lee JM, Jung JH, Hwang D, et al. Coronary Flow Reserve and Microcirculatory Resistance in Patients With Intermediate Coronary Stenosis. *J Am Coll Cardiol.* 2016; 67(10): 1158–1169, doi: [10.1016/j.jacc.2015.12.053](https://doi.org/10.1016/j.jacc.2015.12.053), indexed in Pubmed: [26965536](https://pubmed.ncbi.nlm.nih.gov/26965536/).
  7. Bozbas SS, Eroglu S, Ozyurek BA, et al. Coronary flow reserve is impaired in patients with obstructive sleep apnea. *Ann Thorac Med.* 2017; 12(4): 272–277, doi: [10.4103/atm.ATM\\_195\\_16](https://doi.org/10.4103/atm.ATM_195_16), indexed in Pubmed: [29118860](https://pubmed.ncbi.nlm.nih.gov/29118860/).
  8. Kelshiker MA, Seligman H, Howard JP, et al. Coronary Flow Outcomes Reviewing Committee. Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis. *Eur Heart J.* 2022; 43(16): 1582–1593, doi: [10.1093/eurheartj/ehab775](https://doi.org/10.1093/eurheartj/ehab775), indexed in Pubmed: [34849697](https://pubmed.ncbi.nlm.nih.gov/34849697/).
  9. Gill GS, Gadre A, Kanmanthareddy A. Comparative efficacy and safety of adenosine and regadenoson for assessment of fractional flow reserve: A systematic review and meta-analysis. *World J Cardiol.* 2022; 14(5): 319–328, doi: [10.4330/wjc.v14.i5.319](https://doi.org/10.4330/wjc.v14.i5.319), indexed in Pubmed: [35702325](https://pubmed.ncbi.nlm.nih.gov/35702325/).
  10. Nair PK, Marroquin OC, Mulukutla SR, et al. Clinical utility of regadenoson for assessing fractional flow reserve. *JACC Cardiovasc Interv.* 2011; 4(10): 1085–1092, doi: [10.1016/j.jcin.2011.07.011](https://doi.org/10.1016/j.jcin.2011.07.011), indexed in Pubmed: [22017933](https://pubmed.ncbi.nlm.nih.gov/22017933/).
  11. Edward JA, Lee JH, White CJ, et al. Intravenous regadenoson with aminophylline reversal is safe and equivalent to intravenous adenosine infusion for fractional flow reserve measurements. *Clin Cardiol.* 2018; 41(10): 1348–1352, doi: [10.1002/clc.23052](https://doi.org/10.1002/clc.23052), indexed in Pubmed: [30125368](https://pubmed.ncbi.nlm.nih.gov/30125368/).
  12. Stolker JM, Lim MJ, Shavelle DM, et al. Pooled comparison of regadenoson versus adenosine for measuring fractional flow reserve and coronary flow in the catheterization laboratory. *Cardiovasc Revasc Med.* 2015; 16(5): 266–271, doi: [10.1016/j.carrev.2015.05.011](https://doi.org/10.1016/j.carrev.2015.05.011), indexed in Pubmed: [26242981](https://pubmed.ncbi.nlm.nih.gov/26242981/).
  13. Ghimire G, Hage FG, Heo J, et al. Regadenoson: a focused update. *J Nucl Cardiol.* 2013; 20(2): 284–288, doi: [10.1007/s12350-012-9661-3](https://doi.org/10.1007/s12350-012-9661-3), indexed in Pubmed: [23229649](https://pubmed.ncbi.nlm.nih.gov/23229649/).
  14. Lachmann V, Heimann M, Jung C, et al. Feasibility, safety and effectiveness in measuring microvascular resistance with regadenoson. *Clin Hemorheol Microcirc.* 2019; 71(3): 299–310, doi: [10.3233/CH-180386](https://doi.org/10.3233/CH-180386), indexed in Pubmed: [30103305](https://pubmed.ncbi.nlm.nih.gov/30103305/).
  15. Ntalianis A, Trana C, Muller O, et al. Effective radiation dose, time, and contrast medium to measure fractional flow reserve. *JACC Cardiovasc Interv.* 2010; 3(8): 821–827, doi: [10.1016/j.jcin.2010.06.006](https://doi.org/10.1016/j.jcin.2010.06.006), indexed in Pubmed: [20723854](https://pubmed.ncbi.nlm.nih.gov/20723854/).
  16. Pijls NHJ, van Nunen LX. Fractional flow reserve, maximum hyperemia, adenosine, and regadenoson. *Cardiovasc Revasc Med.* 2015; 16(5): 263–265, doi: [10.1016/j.carrev.2015.06.003](https://doi.org/10.1016/j.carrev.2015.06.003), indexed in Pubmed: [26242980](https://pubmed.ncbi.nlm.nih.gov/26242980/).
  17. van Nunen LX, Lenders GD, Schampaert S, et al. Single bolus intravenous regadenoson injection versus central venous infusion of adenosine for maximum coronary hyperaemia in fractional flow reserve measurement. *EuroIntervention.* 2015; 11(8): 905–913, doi: [10.4244/EIJY14M08\\_10](https://doi.org/10.4244/EIJY14M08_10), indexed in Pubmed: [25136887](https://pubmed.ncbi.nlm.nih.gov/25136887/).
  18. Lim WH, Koo BK, Nam CW, et al. Variability of fractional flow reserve according to the methods of hyperemia induction. *Catheter Cardiovasc Interv.* 2015; 85(6): 970–976, doi: [10.1002/ccd.25752](https://doi.org/10.1002/ccd.25752), indexed in Pubmed: [25413590](https://pubmed.ncbi.nlm.nih.gov/25413590/).

19. Arumugham P, Figueredo VM, Patel PB, et al. Comparison of intravenous adenosine and intravenous regadenoson for the measurement of pressure-derived coronary fractional flow reserve. *EuroIntervention*. 2013; 8(10): 1166–1171, doi: [10.4244/EIJV8I10A180](https://doi.org/10.4244/EIJV8I10A180), indexed in Pubmed: [23164748](https://pubmed.ncbi.nlm.nih.gov/23164748/).
20. Prasad A, Zareh M, Doherty R, et al. Use of regadenoson for measurement of fractional flow reserve. *Catheter Cardiovasc Interv*. 2014; 83(3): 369–374, doi: [10.1002/ccd.25055](https://doi.org/10.1002/ccd.25055), indexed in Pubmed: [23765847](https://pubmed.ncbi.nlm.nih.gov/23765847/).

## Tables and figures

<b>Table 1.</b> Baseline characteristic of patients	
<b>Selected indices</b>	<b>Overall group n = 44</b>
<b>Age – years</b>	66.82 (± 8.02)
<b>Male sex – No. (%)</b>	37 (84.09%)
<b>Body mass index (kg/ m<sup>2</sup> )</b>	27.72 (24.9–30.17)
<b>Hospitalisation time (days)</b>	3 (2.0–5.25)
<b>SBP (mmHg)</b>	139.39 (± 22.2)
<b>DBP (mmHg)</b>	83.55 (± 11.48)
<b>Heart rate</b>	71.27 (± 13.53)
<b>NYHA class</b>	
<b>I</b>	17 (38.64%)
<b>II</b>	9 (20.45%)
<b>II/III</b>	4 (9.09%)
<b>III</b>	9 (20.45%)
<b>CCS class</b>	
<b>I</b>	24 (54.54%)
<b>II</b>	9 (20.45%)
<b>II/III</b>	2 (4.55%)
<b>III</b>	3 (6.82%)
<b>III/IV</b>	1 (2.27%)

All data are expressed as absolute numbers (percentages), means (± SD) or medians (Q1–Q3).

CCS —Canadian Cardiovascular Society; DBP — diastolic blood pressure; NYHA — New York Heart Association; SBP — systolic blood pressure

<b>Table 2. Clinical characteristic of patients</b>	
<b>Selected indices</b>	<b>Overall group n = 44</b>
<b>CAD</b>	41 (93.18%)
<b>Arterial hypertension</b>	38 (86.36%)
<b>Hyperlipidaemia</b>	35 (79.55%)
<b>Overweight</b>	30 (68.18%)
<b>Prior PCI</b>	28 (63.64%)
<b>Prior MI</b>	25 (56.82%)
<b>Smoking</b>	16 (36.36%)
<b>Diabetes myelitis</b>	13 (29.55%)
<b>Heart failure</b>	13 (29.55%)
<b>Atrial fibrillation</b>	8 (18.18%)
<b>Stroke/TIA</b>	5 (11.36%)
<b>Prior PTA/CAS</b>	4 (9.09%)
<b>Kidney failure</b>	4 (9.09%)
<b>Hypothyroidisms</b>	4 (9.09%)

All data are expressed as absolute numbers (percentages).

CAD — coronary artery disease; MI — myocardial infarction; PCI — percutaneous coronary intervention; PTA/CAS — percutaneous transluminal angioplasty/carotid artery stenting; TIA — transient ischemic attack

<b>Table 3. Biochemical indices</b>	
<b>Selected indices</b>	<b>Overall group n = 44</b>
<b>Total cholesterol [mmol/L]</b>	3.75 (3.2–4.45)
<b>LDL [mmol/L]</b>	1.9 (1.4–2.55)

<b>HDL [mmol/L]</b>	1.1 (1–1.32)
<b>TG [mmol/L]</b>	1.3 (0.98–2.26)
<b>Creatinine [<math>\mu\text{mol/L}</math>]</b>	94.2 (76.33–110.5)
<b>MDRD eGFR [ml/min/1.73m<sup>2</sup>]</b>	68.5 (61–89.25)
<b>TSH [<math>\mu\text{IU/mL}</math>]</b>	1.39 (0.98–2.14)
<b>WBC [<math>10^3/\mu\text{L}</math>]</b>	8.27 ( $\pm$ 2.23)
<b>RBC [<math>10^6/\mu\text{L}</math>]</b>	4.6 ( $\pm$ 0.48)
<b>HGB [g/dL]</b>	14.21 ( $\pm$ 1.4)
<b>HCT [%]</b>	41.75 (38.75–43.42)
<b>PLT [<math>10^3/\mu\text{L}</math>]</b>	219 (193.5–256.25)

All data are expressed as absolute numbers (percentages), means ( $\pm$  SD) or medians (Q1–Q3).

eGFR — estimated glomerular filtration rate; HCT — hematocrit; HDL — high-density lipoprotein; HGB — hemoglobin; LDL — low-density lipoprotein; MDRD, RBC — red blood cells; PLT — platelets; TG — triglycerides; TSH — thyroid stimulating hormone; WBC — white blood cells



<b>Table 4. Pharmacotherapy</b>	
<b>Selected indices</b>	<b>Overall group n = 44</b>
<b>ASA</b>	39 (88.64%)
<b>Statin</b>	37 (84.09%)
<b>Beta-blocker</b>	33 (75%)
<b>ACEI</b>	27 (61.36%)
<b>PPI</b>	21 (47.73%)
<b>Diuretic</b>	14 (31.82%)
<b>CCB</b>	11 (25%)
<b>P2Y<sub>12</sub> inhibitor</b>	8 (18.18%)
<b>OACs</b>	7 (15.91%)
<b>Clopidogrel</b>	7 (15.91%)
<b>Insulin</b>	6 (13.64%)
<b>Levothyroxine</b>	2 (4.55%)

All data are expressed as absolute numbers (percentages).

ACEI — angiotensin-converting enzyme inhibitors; ASA — acetylsalicylic acid; CCB — calcium channel blockers; OAC — oral anticoagulants; PPI — proton-pump inhibitors

<b>Table 5. Echocardiography parameters</b>	
<b>Selected indices</b>	<b>Overall group n = 44</b>
<b>LVEF [%]</b>	46.77 ( $\pm$ 15.15)
<b>Akinesia</b>	14 (31.82%)
<b>Hypokinesia</b>	23 (52.27%)
<b>Arrhythmia</b>	8 (18.18%)

All data are expressed as absolute numbers (percentages) and mean ( $\pm$  SD).


LVEF — left ventricle ejection fraction

<b>Table 6. Quantitative differences in outcomes of coronary functional assessment with use of regadenoson vs. adenosine</b>
--


<b>Parameter</b>	<b>Overall group (n = 44)</b>
$\Delta$ FFR	0.02 (0.01–0.04)
$\Delta$ CFR	0.6 (0.29–1.55)
$\Delta$ IMR	3.5 (1.38–7.1)

All data are expressed as median (Q1–Q3).

CFR — coronary flow reserve; FFR — fractional flow reserve; IMR — index of microcirculatory resistance



**Figure 1.** Coronary functional assessment with use of regadenoson and adenosine. Panel **A**, **B**, and **C** show results of measurements (fractional flow reserve [FFR], coronary flow reserve [CFR], and index of microcirculatory resistance [IMR], respectively) in each patient (n = 44) performed with adenosine and regadenoson subsequently. Differences between averaged values obtained using adenosine and regadenoson did not reach statistical significance ( $p = 0.459$  for panel A,  $p = 0.964$  for panel B and  $p = 0.745$  for panel C)



**Figure 2.** Predictors of change size in coronary circulation measurement values assessed using adenosine vs. regadenoson – linear regression models. **A.** Beta coefficients regarding predictors of  $\Delta$ FFR; **B.** Beta coefficients regarding predictors of  $\Delta$ CFR; **C.** Beta coefficients regarding predictors of  $\Delta$ IMR. <sup>a</sup>As compared to NYHA class I; ASA — acetylsalicylic acid; CAD — coronary artery disease; CAS — carotid artery stenting; CFR — coronary flow reserve; FFR — fractional flow reserve; IMR — index of microcirculatory resistance; LVED — left ventricle ejection disease; NYHA — New York Heart Association; OAC — oral anticoagulants; PTA — peripheral transluminal angioplasty; TIA — transient ischemic attack